OTCMKTS:ZYXI - Zynex Stock Price, Forecast & News

Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."

Zynex Inc. (OTCMKTS:ZYXI) released its quarterly earnings results on Tuesday, October, 29th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.00. The business earned $11.82 million during the quarter, compared to the consensus estimate of $11.06 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. View Zynex's Earnings History.

Zynex updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.3-45.8 million, compared to the consensus revenue estimate of $44.11 million.

2 analysts have issued twelve-month price objectives for Zynex's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Zynex's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Zynex.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.

Media headlines about ZYXI stock have been trending negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zynex earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Zynex.

Some companies that are related to Zynex include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Stereotaxis (STXS), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Soleno Therapeutics (SLNO), Rockwell Medical (RMTI), Fonar (FONR), BioSig Technologies (BSGM), Edap Tms (EDAP), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynex investors own include FuelCell Energy (FCEL), Melinta Therapeutics (MLNT), Altria Group (MO), Penumbra (PEN), Aldeyra Therapeutics (ALDX), BioDelivery Sciences International (BDSI), Codexis (CDXS), Catalyst Pharmaceuticals (CPRX), HEXO (HEXO) and Heron Therapeutics (HRTX).

Zynex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Calamos Advisors LLC (0.77%). Company insiders that own Zynex stock include Daniel J Moorhead and Thomas Sandgaard. View Institutional Ownership Trends for Zynex.

ZYXI stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC. Company insiders that have sold Zynex company stock in the last year include Daniel J Moorhead and Thomas Sandgaard. View Insider Buying and Selling for Zynex.

Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZYXI stock can currently be purchased for approximately $10.37.

Zynex has a market capitalization of $339.54 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. View Additional Information About Zynex.

The official website for Zynex is http://www.zynexmed.com/.

Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]